EXELDERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EXELDERM (EXELDERM).
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
| Metabolism | Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation. |
| Excretion | Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible. |
| Half-life | Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours. |
| Protein binding | Not applicable; systemic levels are undetectable with topical use. |
| Volume of Distribution | Not applicable; negligible systemic absorption. |
| Bioavailability | Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption. |
| Onset of Action | Topical: improvement may be seen within 2-3 days of twice-daily application. |
| Duration of Action | Topical: symptomatic relief persists for 12 hours after application, but treatment should continue for full duration (2-4 weeks) to achieve mycological cure. |
Apply a thin layer to affected skin twice daily (morning and evening).
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations. |
| Geriatric use | No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EXELDERM (EXELDERM).
| Breastfeeding | Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available. |
| Teratogenic Risk | Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed. |
| Fetal Monitoring | Monitor maternal skin reactions; fetal monitoring not typically required unless systemic effects suspected. |
■ FDA Black Box Warning
None.
| Common Effects | Skin atrophy Telangiectasia Skin irritation Dry skin |
| Serious Effects |
Known hypersensitivity to sulconazole or any component of the formulation.
| Precautions | Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established. |
| Food/Dietary | None known. |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility. |
| Clinical Pearls | Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings. |
| Patient Advice | Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds. · Wash hands before and after applying unless treating hands. · Do not cover the treated area with bandages or wrappings unless directed by a doctor. · Stop use and consult doctor if condition worsens or does not improve within 2 weeks. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. |